Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly.
The adverse gastrointestinal effects of octreotide, a synthetic analog of somatostatin, have not been fully elucidated. Low-dose octreotide frequently causes adverse gastrointestinal symptoms in normal individuals. We investigated the adverse gastrointestinal effects of high-dose octreotide, which is required for the normalization of growth hormone hypersecretion in some patients with acromegaly. Patients with acromegaly (N = 8) were treated with octreotide, 450 micrograms/day, then 1500 micrograms/day for two months at each dosage. Carbohydrate absorption was assessed using the D-xylose test, and fat absorption using fecal fat excretion and serum carotene concentrations, at baseline, at each dosage of octreotide, and after one month of washout. Ultrasonography was used to monitor for cholelithiasis. Growth hormone and insulin-like growth factor-I concentrations were significantly suppressed at both dosages. Adverse gastrointestinal symptoms were mild and transient. D-Xylose absorption remained normal at each dosage and after one month of washout. Fecal fat excretion increased from 7 +/- 2 to 12 +/- 2 g/24 hr (P < 0.05) after the higher dosage and resumed baseline levels after the washout. Mean fasting serum carotene levels remained normal, and carotene loading test (15,000 units three times a day for three days) was unreliable in identifying patients with high fecal fat. No new cholelithiasis was detected by ultrasonography. One of two patients with preexisting cholelithiasis developed biliary colic several days after the treatment period. Although steatorrhea was common, small intestinal absorptive capacity was otherwise unchanged by four months of high-dose octreotide treatment, which significantly suppressed growth hormone secretion in acromegalic patients.
Ho
P J
PJ
Department of Internal Medicine, Department of Veterans Affairs Medical Center, Ann Arbor, Michigan.
Boyajy
L D
LD
Greenstein
E
E
Barkan
A L
AL
D000172:Acromegaly / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D000328:Adult; D002338:Carotenoids / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005243:Feces / Q000737:chemistry; D005260:Female; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects*; D008055:Lipids / Q000032:analysis; D008286:Malabsorption Syndromes / Q000097:blood / Q000139:chemically induced / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D014994:Xylose / Q000378:metabolism
D008055:Lipids; D002338:Carotenoids; D014994:Xylose; D015282:Octreotide